Antibody Cocktails Lose Potency Against Omicron Super-Mutant, Early Tests Show


DB: The antibody cocktail given to disgraced former president Donald Trump when he was struck down with COVID-19 last year appears to lose some effectiveness when faced with the heavily mutated Omicron variant.

The Wall Street Journal first reported on the results of preliminary tests from drugmaker Regeneron that appear to show a faded effectiveness of its antibody treatment against Omicron when compared to earlier mutations.

However, Regeneron said it won’t be able to say exactly how big of an impact the variant has on its treatment until further testing is carried out in the next few weeks. Dr. George Yancopoulos, Regeneron’s president, said the company is already testing alternative antibodies that could tackle Omicron if it is proven to cause a significant loss of efficacy.

“What we have to admit is, in the course of the past six days, our urgency has increased,” Yancopoulos told the newspaper. “What started out as a backup plan has now been made a lot more urgent.” Antibody cocktails are the only drugs that have been authorized to treat patients infected with COVID-19.

Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy


  1. “What we have to admit is, in the course of the past six days, our urgency has increased,”

    The “foot soldiers” in this operation must derive much job satisfaction from the nature of their objective. 🧐

  2. Wait a minute. If the Omicrone variant just came on the scene, how did Regeneron have time to find enough test subjects for their antibody “medicines”? Why does VT continue to post this drivel without at least a little screening. Oh, I know. In their Vaxx vs. Antivaxx ballgame, this sort of stuff counts as a point for Vaxx. I think.

Comments are closed.